CVE-2022-26235A vulnerability was discovered in the Remisol Advance v2.0.12.1 and below for the Normand Message Server.
Updated under an hour ago ()
Does this affect you?
It affects beckmancoulter remisol_advance. Add what you run to find out whether that includes you.
EPSS puts the chance of exploitation in the next 30 days at 0.19%, higher than 8% of scored CVEs.
Do this next
Free account, 1 product
A vulnerability was discovered in the Remisol Advance v2.0.12.1 and below for the Normand Message Server. On installation, the permissions set by Remisol Advance allow non-privileged users to overwrite and/or manipulate executables and libraries that run as the elevated SYSTEM user on Windows.
- CVSS
- 7.8 HIGH (v3.1, NVD)CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
- Weakness (CWE)
- Not given
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- 0.19% (percentile 8)
- Assigned by
- mitre
- NVD analysis
- Modified
- Record last updated
- Aug 3, 2024
- First seen by InfoSec Signals
- Oct 12, 2026
Affected products
beckmancoulter remisol_advance beckmancoulter:remisol_advance | through 2.0.12.1 | NVD |
References
- https://www.beckmancoulter.com/products/clinical-information-management-tools/remisol-advanceproduct, vendor-advisory
- https://pastebin.com/amgw9pE7third-party-advisory
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.